Search - tctmd.com

Displaying 281 - 300 of 410

Sort: Relevancy | Date

News Conference News TCT 2016

RIBS VI：Absorb BVS 支架内再狭窄方面安全，但没有好过 Xience 金属支架

Michael O'Riordan

November 08, 2016

News Conference News TCT 2016

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

Shelley Wood

November 07, 2016

News Conference News TCT 2016

TRANSFORM-OCT: 生物可吸收和耐久聚合物 DES 早期和晚期愈合率类似

Michael O'Riordan

November 02, 2016

News Conference News TCT 2016

TRANSFORM-OCT: Similar Early and Late Healing With Bioresorbable- and Durable-Polymer DES

Michael O'Riordan

November 02, 2016

News Conference News TCT 2016

TRANSFORM-OCT: Similar Curación Precoz y Tardía con SLF Bioreabsorbibles y de Polímero Duradero

Michael O'Riordan

November 02, 2016

News Conference News TCT 2016

ReACT: Routine Angiographic Follow-up After PCI Does Not Lower Clinical Events

Michael O'Riordan

November 01, 2016

News Conference News TCT 2016

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

Yael L. Maxwell

October 31, 2016

News Conference News TCT 2016

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

Todd Neale

October 31, 2016

News Conference News TCT 2016

Interventionalists Push Transradial PCI in Wider Range of Settings, Including ACS, CTOs, and Calcified Lesions

Michael O'Riordan

October 31, 2016

News Conference News TCT 2016

EXCEL 和 NOBLE：左主干 PCI/CABG 的选择结果相悖

Michael O'Riordan

October 31, 2016

News Conference News TCT 2016

EXCEL y NOBLE: Los Resultados Contrarios Plantean un Dilema a la Hora de Elegir entre PCI y CABG en el Manejo de la Enfermedad de Tronco Coronario Izdo.

Michael O'Riordan

October 31, 2016

News Conference News TCT 2016

EXCEL and NOBLE: Opposing Results Pose Quandary for PCI/CABG Choice in Left Main Disease

Michael O'Riordan

October 31, 2016

News Conference News TCT 2016

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

TCT Daily Staff

October 30, 2016

News Conference News TCT 2016

LEADERS FREE: Polymer-Free DES Maintains Superior Safety, Efficacy Over BMS at 2 Years

Yael L. Maxwell

October 30, 2016

News Conference News TCT 2016

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Michael O'Riordan

October 30, 2016

News Conference News TCT 2016

DES With Biodegradable Polymers Stand Up Well Against Durable-Polymer Stents in the Short Term

Todd Neale

October 30, 2016

News Conference News VIVA 2016

Longer Term, IN.PACT SFA Trial and Global Registry Continue to Support DCB Therapy as an Option

L.A. McKeown

October 12, 2016

News Conference News VIVA 2016

Bioresorbable Scaffold Shows Sustained Promise in Superficial Femoral and Iliac Artery Lesions

L.A. McKeown

September 22, 2016

News Conference News VIVA 2016

Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear

L.A. McKeown

September 21, 2016

News Conference News VIVA 2016

Positive Results Continue at 2 Years for Paclitaxel-Eluting PAD Stent

L.A. McKeown

September 20, 2016

Advertisement

RIBS VI：Absorb BVS 支架内再狭窄方面安全，但没有好过 Xience 金属支架

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

TRANSFORM-OCT: 生物可吸收和耐久聚合物 DES 早期和晚期愈合率类似

TRANSFORM-OCT: Similar Early and Late Healing With Bioresorbable- and Durable-Polymer DES

TRANSFORM-OCT: Similar Curación Precoz y Tardía con SLF Bioreabsorbibles y de Polímero Duradero

ReACT: Routine Angiographic Follow-up After PCI Does Not Lower Clinical Events

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

Interventionalists Push Transradial PCI in Wider Range of Settings, Including ACS, CTOs, and Calcified Lesions

EXCEL 和 NOBLE：左主干 PCI/CABG 的选择结果相悖

EXCEL y NOBLE: Los Resultados Contrarios Plantean un Dilema a la Hora de Elegir entre PCI y CABG en el Manejo de la Enfermedad de Tronco Coronario Izdo.

EXCEL and NOBLE: Opposing Results Pose Quandary for PCI/CABG Choice in Left Main Disease

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

LEADERS FREE: Polymer-Free DES Maintains Superior Safety, Efficacy Over BMS at 2 Years

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

DES With Biodegradable Polymers Stand Up Well Against Durable-Polymer Stents in the Short Term

Longer Term, IN.PACT SFA Trial and Global Registry Continue to Support DCB Therapy as an Option

Bioresorbable Scaffold Shows Sustained Promise in Superficial Femoral and Iliac Artery Lesions

Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear

Positive Results Continue at 2 Years for Paclitaxel-Eluting PAD Stent

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content